Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT)
· seekingalpha.com
Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications. Read why COGT stock is a buy.
Cogent Biosciences ( COGT ) looks attractive to me in its current state. The products are all related to the same molecular hypothesis (selective inhibition of ...